Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

This page features the latest news about the Verona Pharma ADR stock. Piper Sandler lifts Verona Pharma shares target citing high COPD drug approval odds On Tuesday, Piper Sandler exhibited confidence ...

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

Sanofi S.A. Part Cert-1.97% €8.03M ...

UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.

1 Day VRNA 2.95% DJIA -0.24% S&P 500 -0.48% Health Care/Life Sciences 0.39% ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

President Trump on Friday vowed to impose sweeping tariffs on semiconductor chips, pharmaceuticals, steel and aluminum and oil and gas. “We’ll be doing pharmaceuticals. Importantly in drugs ...